Collaborations And PartnershipsCureVac announced a multi-target collaboration with MD Anderson for antigen discovery and vaccine development, enhancing its research and development capabilities.
Financial PerformanceCureVac reported FY23 results with cash reserves of €402.5M, alongside plans to streamline the organization and reduce its workforce by approximately 12%, ensuring an operating runway into 4Q25.
Strategic RestructuringCureVac's strategic restructuring focuses resources on the most advanced wholly-owned pipeline assets, extending its cash runway into 2028.